ICE Fight Could Unlock Trump Health Reforms | STAT News

The seemingly unrelated worlds of NFL football and health care reform are colliding in a surprising way, potentially opening a new avenue for advancing President Trump’s “Great Healthcare Plan.” This unexpected connection stems from the current political maneuvering around funding for Immigration and Customs Enforcement (ICE), and a recent revelation about Kansas City Chiefs tight finish Travis Kelce’s pre-NFL job.

Kelce, known for his on-field prowess and recent high-profile relationship, reportedly worked as a telemarketer selling Obamacare before being drafted into the NFL. As STAT News reported, this detail surfaced during a podcast appearance, highlighting the often-unconventional paths people take before achieving fame. While Kelce’s past employment is a curious anecdote, the broader political context is what’s driving a potential shift in health policy.

A Budgetary Gambit and the Path to Reconciliation

Republicans are contemplating using a budget process called reconciliation to fund ICE independently of Democratic support. This strategy, born from disagreements over ICE reforms following incidents in Minneapolis, could inadvertently create an opportunity to push through other legislative priorities, including significant changes to the American health care system. Reconciliation requires only a simple majority in the Senate, bypassing the usual 60-vote threshold needed to overcome a filibuster.

President Trump’s “Great Healthcare Plan” centers around shifting away from the Affordable Care Act’s insurance structure towards a system of health savings accounts (HSAs). The plan too aims to solidify agreements with pharmaceutical companies to align U.S. Drug prices with those in other developed nations and to curtail the influence of pharmacy benefit managers (PBMs). While the drug pricing component faces resistance, health savings accounts appear to be a more viable target for reconciliation, according to Natasha Murphy, director of health policy at the Center for American Progress. As STAT News detailed in January, the path forward for Trump’s plan is complex, but the ICE funding dispute could provide a crucial opening.

The apply of reconciliation isn’t new. Republicans employed the same tactic last year to pass tax legislation. Though, with a narrow margin in the House and recent tax cuts already enacted, securing enough support for further legislative changes will be challenging. Senator Rick Scott (R-Fla.) noted that last year’s tax cuts were the unifying factor that enabled the use of reconciliation, a condition that doesn’t currently exist.

Beyond ICE: CDC Leadership and Vaccine Policy

The political climate extends beyond funding disputes and into the realm of public health agencies. The Centers for Disease Control and Prevention (CDC) is currently without a permanent director, and the nomination process has been fraught with controversy. Acting Director Jay Bhattacharya recently held an all-hands meeting with agency staff, as reported by Helen Branswell of STAT News, where he addressed questions about his leadership and defended Health Secretary Robert F. Kennedy Jr. The announcement of a permanent director is expected soon, but the agency remains in a state of flux.

This leadership uncertainty coincides with legal challenges to the recent reconstitution of the Advisory Committee on Immunization Practices (ACIP) and changes to the childhood vaccine schedule. A federal judge has issued a preliminary ruling suggesting that these changes were likely unlawful due to the manner in which they were implemented. These developments underscore the broader political tensions impacting public health decision-making.

Addressing Insulin Costs: A Bipartisan Effort

In a rare display of bipartisan cooperation, lawmakers have introduced the INSULIN Act of 2026, aiming to cap out-of-pocket insulin costs at $35 per month for individuals with private insurance and to lower costs for some uninsured individuals through a pilot program. This builds upon existing legislation that already caps insulin prices for Medicare patients. The bill, supported by Senators Raphael Warnock (D-Ga.), Jeanne Shaheen (D-N.H.), John Kennedy (R-La.), and Susan Collins (R-Maine), seeks to increase competition among insulin manufacturers and address the role of pharmacy benefit managers. Semafor first reported on the agreement.

This effort is further bolstered by action from the Federal Trade Commission (FTC), which has reached proposed settlements with CVS Caremark and Cigna’s Express Scripts over allegations of artificially inflating insulin prices. Ed Silverman of STAT News’ Pharmalot provides detailed coverage of these developments, highlighting the growing scrutiny of PBM practices.

What Comes Next: A Fluid Situation

The interplay between the ICE funding debate, the push for health care reforms, and the ongoing challenges at the CDC creates a highly fluid situation. Whether Republicans will ultimately attempt to use reconciliation remains uncertain. The success of such a maneuver will depend on their ability to overcome internal divisions and secure the necessary votes. The coming weeks will be critical in determining the fate of President Trump’s health care agenda and the future direction of public health policy in the United States. The process will likely involve further negotiations, potential compromises, and continued scrutiny from both sides of the political aisle. Ongoing monitoring of legislative developments and agency actions will be essential to understanding the evolving landscape.